Navigation Links
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
Date:3/21/2011

VPRIV Important Safety Information

The most serious adverse reactions seen with VPRIV were hypersensitivity reactions. Infusion-related reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of infusion-related reactions were: headache, dizziness, low or high blood pressure, nausea, tiredness and weakness, and fever.  Generally the infusion-related reactions were mild and, in treatment-naïve patients, onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time.  

All adult side effects of VPRIV are considered relevant to children (ages 4 to 17 years). Side effects more commonly seen in children compared with adult patients included: upper respiratory tract infection, rash, aPTT prolonged, and fever. The safety of VPRIV has not been established in patients younger than 4 years of age.

As with all therapeutic proteins, there is a potential for immunogenicity. In the clinical studies 1 of 54 treatment-naïve patients treated with VPRIV developed IgG class antibodies.  It is unknown if the presence of IgG antibodies to VPRIV is associated with a higher risk of infusion reactions. 

VPRIV is not available in all countries and prescribing information may differ between countries.  Please consult your local prescribing information.  Full prescribing information for VPRIV in the US can be found at www.VPRIV.com.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
2. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
3. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
4. Reportlinker Adds Shire plc: PharmaVitae Profile
5. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
6. Shire plc - Statement re ProAmatine
7. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
10. Shire plc Appoints Two New Board Directors
11. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna ... McKenna, DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ ... of an otherwise non-healing surgical knee wound. , The case involved a 78-year-old ...
(Date:8/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... United Kingdom -based Lab M Holdings, ... and diagnostic systems. Lab M was ... provider of microbial testing and diagnostic products for the ... company currently sells into more than 70 countries worldwide, ...
(Date:8/27/2015)... ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... three and six-month periods ended June 30, 2015. Biorem,s complete second ... www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ... , 2014 , 2015 , 2014 ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... needs and expertly narrows down the product choices to a manageable shortlist of ... down the list to models that fit best with the customer’s industry and ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Neogen acquires U.K.-based Lab M Holdings 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3METTLER TOLEDO Updates Online Scale Selection Tool 2
... Westerners Return from Beijing,s World-Class Stem Cell Treatment ... with Clear Improvement, Giving Hope Not Found ... Puhua Neurosurgical,Hospital, the world,s leading center for effective ... today here announced that four more,international patients returned ...
... Strategic Focus on Growth-Driving Global Products, BASINGSTOKE, ... SHPGY, TSX: SHQ), the global specialty biopharmaceutical,company, announces ... of non core,products to Almirall for a cash ... SOLARAZE(R) (3% gel diclofenac sodium),and VANIQA(R) (eflornithine hydrochloride), ...
... more about the origins of quantum dot blinking, ... National Laboratory, the University of Chicago and the ... to characterize it on faster time scales than ... material, also known as quantum dots, are being ...
Cached Biology Technology:American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 2American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 3American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 4Shire Divests Non-Core Product Portfolio to Almirall 2Shire Divests Non-Core Product Portfolio to Almirall 3Argonne researcher studies what makes quantum dots blink 2
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that four of its fingerprint ... have officially been named FIDO Certified™ by the ... the certification, Synaptics, Natural ID™ fingerprint solutions are ... Framework (UAF) standard and are interoperable among other ...
(Date:8/6/2015)... and TELTOW, Germany , August 6, ... Conference, SensoMotoric Instruments (SMI) shows the world,s ... , based on Epson,s Moverio BT-200 see-through head ... With this new solution, unprecedented quality and efficiency is ... with context-sensitive displays. For the first time, professionals and ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... A new minute freshwater snail species belonging to the genus ... Athens (Canella Radea) in a spring covered by snow on ... access journal Zookeys . The ... shell, grey-black pigmented soft body and a black penis with a ...
... scientists may lead to a pharmaceutical breakthrough for a ... cells that line the inner surfaces of our body,s ... the FASEB Journal ( http://www.fasebj.org ), the ... small-molecule drug candidates which help cells bypass defective channels ...
... how humans develop immunity to malaria, and could ... Dr Alyssa Barry from the Walter and ... using ,protein microarray, technology to screen human blood ... the malaria-causing Plasmodium falciparum parasite. Her research, which ...
Cached Biology News:Scientists discover new drug candidates for cystic fibrosis and other diseases 2'Protein microarrays' may reveal new weapons against malaria 2
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... Product Goat polyclonal to Cholesterol Oxidase ... Reactivity / Specificity Cross-reacts with bacteria. ... Background Information Cholesterol oxidases exist as ... and are implicated in bacterial pathogenesis. In ...
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
... anti-phospho-PTEN (Ser385) ... amino acid region encompassing the ... (Ser385), Accession ... Quality Assurance: Routinely ...
Biology Products: